GPX4 is upregulated in many patients with lung cancers and causes resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), radiotherapy, and immune checkpoint inhibitors [15]. Here, EGFR is linked to lung cancer.